{
  "stage": "S3",
  "passed": false,
  "convergence_score": 0.724,
  "convergence_threshold": 0.85,
  "convergence_pass": false,
  "jaccard": 0.2425,
  "jaccard_threshold": 0.85,
  "jaccard_pass": false,
  "type_01_ratio": 0.4,
  "type_01_threshold": 0.75,
  "type_pass": false,
  "cosine": 0.724,
  "jsd": 0.2232,
  "kappa": 0.9378,
  "type_distribution": {
    "0": 0.0,
    "1": 0.4,
    "2": 0.4,
    "3": 0.2
  },
  "divergence_map": {
    "total_unique_claims": 16,
    "most_divergent": [
      {
        "statement": "1:** Therapeutic neuroplasticity occurs at ~15-50% 5-HT2A occupancy, where Gq/11-PLC-IP3/DAG signaling dominates, activating mTOR-dependent BDNF expression and dendritic spine growth in prefrontal cortex.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.8
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "2:** Above ~60% occupancy, \u03b2-arrestin 2 recruitment increases supralinearly due to cooperative binding at 5-HT2A/mGluR2 heterodimers, uncoupling mGluR2 inhibitory signaling and producing excessive layer V cortical glutamate release.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          2
        ],
        "confidences": [
          0.65
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "3:** The therapeutic index is ~10-15 (ED50 plasticity ~3-5 mg oral psilocybin; TD50 destabilization ~40-60 mg), consistent with FDA TI \u2265 10 prior, and this ratio is governed by the ~3-5\u00d7 concentration gap between Gq EC50 and \u03b2-arrestin 2 EC50 at 5-HT2A.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          2
        ],
        "confidences": [
          0.7
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "4:** Psilocin Ki at 5-HT2A is 6-25 nM (pKi ~7.6-8.2), and with Hill coefficient ~1 (non-cooperative single-site), occupancy follows standard hyperbolic kinetics\u2014the apparent nonlinearity at ~60% is an emergent property of downstream pathway coupling, not receptor binding itself.",
        "models_supporting": [
          "claude"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.9
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "1:** Psilocybin\u2019s therapeutic window (20\u201350% 5-HT2A occupancy) is defined by preferential Gq/11-PLC activation, driving BDNF/mTOR-mediated neuroplasticity in prefrontal cortex (PFC) without network desynchronization.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.85
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "2:** Perceptual destabilization at >60% occupancy results from \u03b2-arrestin 2 recruitment to 5-HT2A/mGluR2 heterodimers, uncoupling mGluR2\u2019s inhibitory brake on glutamate release and causing thalamocortical desynchronization.",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.75
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "3:** The therapeutic index (TD50/ED50) of ~10\u201315 for psilocybin is constrained by the abrupt \u03b2-arrestin 2 recruitment threshold at >60% occupancy, aligning with FDA\u2019s minimum safety margin (PRIOR: therapeutic_index_minimum = 10.0).",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          2
        ],
        "confidences": [
          0.8
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "4:** Psilocin\u2019s Ki at 5-HT2A is 6\u201325 nM (pKi 7.6\u20138.2), with low doses (1\u201310 mg) yielding plasma concentrations of 2\u201320 nM (~10\u201360% occupancy) and high doses (>25 mg) reaching 100\u2013500 nM (>80\u201395% occupancy).",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.9
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "5 (SPECULATIVE):** CYP3A4 inhibition by CBD (threshold = 1.0 \u00b5M) may indirectly widen psilocybin\u2019s therapeutic window by reducing psilocin metabolism, but this effect is negligible at typical CBD doses (PRIOR: CBD_therapeutic_window = 1\u201310 \u00b5M).",
        "models_supporting": [
          "mistral"
        ],
        "types_assigned": [
          3
        ],
        "confidences": [
          0.6
        ],
        "type_variance": 0,
        "n_supporters": 1
      },
      {
        "statement": "Psilocin Kd at human 5-HT2A = 6-25 nM (pKi 7.6-8.2), yielding ~20-50% occupancy at therapeutic 1-10 mg doses ([psilocin] 2-20 nM) and >80% at high >25 mg ([psilocin] >100 nM).",
        "models_supporting": [
          "grok"
        ],
        "types_assigned": [
          1
        ],
        "confidences": [
          0.93
        ],
        "type_variance": 0,
        "n_supporters": 1
      }
    ],
    "models_present": [
      "claude",
      "mistral",
      "grok",
      "gemini",
      "deepseek"
    ]
  },
  "recommendation": "S3 gate FAILED. The system did not converge to stable consensus. This indicates genuine scientific disagreement worth investigating. Review the divergence map below."
}